Italia markets closed

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
5,63-0,20 (-3,43%)
Alla chiusura: 04:00PM EDT
5,75 +0,12 (+2,13%)
Dopo ore: 07:40PM EDT

Editas Medicine, Inc.

11 Hurley Street
Cambridge, MA 02141
United States
617 401 9000
https://www.editasmedicine.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno265

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Gilmore O'Neill M.D.President, CEO & Director1,04MN/D1964
Mr. Erick J. Lucera C.F.A., CPACFO & Executive VP911,46kN/D1968
Dr. Linda C. Burkly Ph.D.Executive VP & Chief Scientific Officer522,44kN/D1957
Dr. Baisong Mei M.D., Ph.D.Executive VP & Chief Medical Officer654,9kN/D1964
Dr. Feng Zhang Ph.D.Co-Founder & Scientific Advisory Board MemberN/DN/DN/D
Dr. George McDonald Church Ph.D.Co-Founder & Scientific Advisory Board MemberN/DN/D1954
Mr. Gregory WhiteheadExecutive VP and Chief Technical & Quality OfficerN/DN/DN/D
Cristi BarnettCorporate Communications & Investor RelationsN/DN/DN/D
Ms. Charlene Stern J.D., Ph.D.Executive VP & General CounselN/DN/DN/D
Ms. Linea AspesiExecutive VP & Chief People OfficerN/DN/D1970
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Editas Medicine, Inc. al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 4; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.